Mimedx Group Inc - MDXG STOCK NEWS

MIMEDX (NASDAQ: MDXG) has announced its participation in three major industry conferences to showcase its latest scientific and clinical data for Advanced Wound Care and Surgical Solutions. The company will be present at:

1. MedStar Georgetown University Hospital's Diabetic Limb Salvage Conference (April 10-12, 2025) featuring a sponsored lunch symposium on limb salvage strategies

2. Symposium on Advanced Wound Care (SAWC) Spring 2025 (April 30-May 4, 2025) including a sponsored lunch symposium on wound healing

3. Digestive Disease Week (DDW) 2025 (May 3-6, 2025) featuring an oral presentation on hospital readmissions and anastamotic leaks in colorectal surgery

CEO Joseph H. Capper emphasized the company's commitment to innovation and expanding their clinical evidence base, particularly highlighting their expansion into gastrointestinal surgery applications.

MIMEDX (Nasdaq: MDXG) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled for March 3-5, 2025, at the Boston Marriott Copley Place. The company's senior management will deliver a presentation on Tuesday, March 4, 2025, at 11:10 AM ET.

The conference will feature presentations, fireside chats, and panel discussions focused on various aspects of the healthcare industry, moderated by TD Cowen research team members. Institutional investors can arrange meetings with MIMEDX senior management through their TD Cowen representatives.

A live webcast of the presentation will be accessible through the Events page in the Investors section of MIMEDX's website, with a replay available after the event.

MIMEDX (NASDAQ: MDXG) reported strong financial results for Q4 and full year 2024. Fourth quarter net sales grew 7% year-over-year to $93 million, while full-year net sales increased 9% to $349 million.

Q4 highlights include GAAP net income of $7 million ($0.05 per share) and Adjusted EBITDA of $20 million (21% of net sales). Gross margin was 82% for Q4 2024, with adjusted gross margin at 84%. The company maintained strong cash position with $104 million in cash and cash equivalents as of December 31, 2024.

Looking ahead to 2025, MIMEDX expects high single-digit net sales growth and Adjusted EBITDA margin above 20%. Long-term outlook projects low double-digit annual net sales growth with continued Adjusted EBITDA margin exceeding 20%.

MIMEDX Group (Nasdaq: MDXG) has announced its upcoming fourth quarter and full year 2024 financial results release, scheduled for after market close on Wednesday, February 26, 2025. The company's senior management team will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results.

Investors can access the conference call through a webcast or by phone, with separate dial-in numbers provided for U.S. (877-407-6184) and international investors (201-389-0877). A replay of the webcast will be available on the MIMEDX website for approximately 30 days following the event.

MIMEDX (NASDAQ: MDXG) has filed a patent infringement lawsuit against Surgenex in the U.S. District Court for the District of Arizona. The lawsuit alleges that several of Surgenex's placental allograft products infringe on MIMEDX's patents, seeking permanent injunctive relief and monetary damages. This is the second lawsuit against Surgenex, following earlier litigation regarding alleged corporate raiding and unfair competitive practices. MIMEDX, holding over 70 patents in the placental allograft category, plans to expand its investigation into potential patent infringements by other competitors amid the increasing number of skin substitutes entering the market.

MIMEDX Group (Nasdaq: MDXG) has announced its senior management's participation in three upcoming investor conferences in December 2024. The schedule includes:

• Mizuho Health Care Conference on Wednesday, December 11, featuring one-on-one sessions in New York, NY
• Northland Growth Conference on Thursday, December 12, with virtual one-on-one sessions
• Stifel MedTech West Coast Bus Tour on Thursday, December 12, offering one-on-one sessions in Palo Alto, CA

Interested investors can arrange meetings with MIMEDX senior management through their respective Mizuho, Northland Capital, or Stifel representatives.

MIMEDX Group (NASDAQ: MDXG) announces significant changes to Local Coverage Determinations (LCDs) for skin substitute grafts, effective February 12, 2025. The revised LCDs include key modifications: patient treatment applications increased from 4 to 8, and treatment duration extended from 12 to 16 weeks. Over 200 unproven skin substitutes will no longer be covered, while MIMEDX's EPIFIX® and EPICORD® remain on the covered products list. The company highlights that Medicare spending on skin substitutes has reached over $1 billion per month, representing a 20-fold increase over five years, which these changes aim to address.

MIMEDX Group (NASDAQ: MDXG) has announced its senior management's participation in two upcoming investor conferences in New York. The company will attend the Stifel Healthcare Conference 2024 on Monday, November 18, with a webcast scheduled for 9:45 AM ET, and the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19. Investors interested in meeting with MIMEDX management at these events should contact their Stifel or Craig-Hallum representatives.

MIMEDX (MDXG) reported Q3 2024 net sales of $84 million, up 3% year-over-year, with GAAP net income of $8 million and earnings per share of $0.05. The company achieved an Adjusted EBITDA of $18 million, representing a 22% margin. Growth was driven by AMNIOEFFECT® and EPIEFFECT® products, along with the newly launched HELIOGEN® product. Gross margin remained stable at 81.8%. The company raised its 2024 net sales growth expectations to high single-digits and maintains its Adjusted EBITDA margin target above 20%.